About
Cnnabinoid-based Cancer Therapies
CNBX Pharmaceuticals is developing a platform that leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based cancer therapies tailored to each patients specific profile. By developing tools to assess effectiveness on a personalized basis, Cannabics seeks to make cannabinoids part of the future of cancer therapy.
CNBX Pharmaceuticals operates In Israel as G.R.I.N Ultra Ltd where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer.
Identity
| Name | CNBX Pharmaceuticals |
|---|---|
| Slug | cnbx-pharmaceuticals |
| Type / kind | startup |
| Source _id | zfWmweZ4JJn7gPfRtgxpsq6VLuEB3dzNr3WLaq103cJqWCavy995zS |
Status
| Status | active |
|---|---|
| Status reason | Public on OTC on Sep, 2017; |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | Tel Aviv-Yafo |
| HQ address | HaBarzel St 11, Tel Aviv-Yafo, 6971017, Israel |
Web & social
| Website | https://cnbxpharma.com/ |
|---|---|
| https://www.linkedin.com/company/2878012 | |
| Twitter / X | https://twitter.com/CNBXPharma |
| YouTube | https://www.youtube.com/channel/UCDv3HpZ8hXk3ezhKmzqx8dA |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyMedical Cannabis
Business models
B2B
Tags
cancermedical-cannabisoncology
Funding
| Total raised | — |
|---|---|
| Current stage | Public |
| Market cap | $222K |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}